Keyphrases
Patient Well-being
100%
Phase III Clinical Trial
100%
Doxorubicin
100%
Soft Tissue Sarcoma
100%
Median Time
44%
Patient-reported Outcomes
33%
Placebo
22%
Physical Function
22%
Phase II Trial
22%
Advanced or Metastatic
22%
Olaratumab
22%
QLQ-C30
22%
EORTC QLQ-C30
22%
Clinical Trials
11%
Clinically Significant
11%
Patient Care
11%
Rapid Decline
11%
Cancer Treatment
11%
Health Status
11%
Health-related Quality of Life
11%
Sarcoma
11%
Nausea-vomiting
11%
Clinical Care
11%
Longitudinal Data
11%
Cumulative Dose
11%
Patient-Reported Outcomes Measurement Information System (PROMIS)
11%
Physical Pain
11%
Patient Perspective
11%
Metastatic Sarcoma
11%
Advanced Soft Tissue Sarcoma
11%
Metastatic Soft Tissue Sarcoma
11%
Advanced Sarcoma
11%
European Organizations
11%
Treatment Cycle
11%
Quality of Life Questionnaire
11%
Patient-reported Outcome Assessment
11%
Brief Pain Inventory-Short Form
11%
Dexrazoxane
11%
Future Care
11%
Medicine and Dentistry
Clinical Trial
100%
Quality of Life
100%
Doxorubicin
100%
Soft Tissue Sarcoma
100%
Patient-Reported Outcome
55%
Growth Hormone
33%
Symptom
22%
Placebo
22%
Sarcoma
22%
Olaratumab
22%
Nausea
11%
Cancer Treatment
11%
Pooled Analysis
11%
Health Status
11%
Outcome Assessment
11%
Brief Pain Inventory
11%
Dexrazoxane
11%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Doxorubicin
100%
Soft Tissue Sarcoma
100%
Growth Hormone
33%
Placebo
22%
Symptom
22%
Sarcoma
22%
Olaratumab
22%
Malignant Neoplasm
11%
Nausea
11%
Health Status
11%
Razoxane
11%
Neuroscience
Doxorubicin
100%
Growth Hormone Treatment
33%
Placebo
22%
Olaratumab
22%
Dexrazoxane
11%